{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:09:25Z","timestamp":1782569365506,"version":"3.54.5"},"reference-count":27,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sealy Center For Vaccine Sciences","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Texas Academy of Family Physicians","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the US incidence of thrombotic events and related rare diagnoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Claims-based retrospective cohort study of incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>US commercial health insurance administrative claims database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults 25\u201364 years of age between 2015 and 2019 with a minimum of 12 consecutive thrombosis-free months of continuous enrolment beginning 2014 were selected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes<\/jats:title>\n                    <jats:p>Age (10-year intervals) and sex stratum-specific incidence rates per 100\u2009000 person-years were determined for venous thromboembolism (VTE), cerebral venous thrombosis (CVT) and other major venous thrombotic events, and events of special interest, including immune thrombocytopenic purpura (ITP), haemolytic-uremic syndrome (HUS) and heparin-induced thrombocytopenia (HIT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 13\u2009249\u2009229 enrollees (half female\/male), incidence of venous thromboembolic events (deep vein thrombosis (DVT), pulmonary embolism (PE), CVT or other major venous thrombotic conditions) was 247.89 per 100\u2009000 person-years (95%\u2009CI: 245.96 to 249.84). Incidence of VTE was 213.79 with ICD codes alone (95%\u2009CI: 211.99 to 215.59) and 129.34 (95% CI: 127.95 to 130.75) when also requiring a filled anticoagulation prescription or an inferior vena cava (IVC) filter. Incidence was 6.37 for CVT (95%\u2009CI: 6.07 to 6.69), 26.06 for ITP (95%\u2009CI: 25.44 to 26.78), 0.94 for HUS (95%\u2009CI: 0.82 to 1.06) and 4.82 for HIT (95%\u2009CI: 4.56 to 5.10). The co-occurrence of CVT with either ITP or HIT (diagnoses within 14 days of one another) was 0.090 (95% CI: 0.06 to 0.13). Incidence tended to increase with age and was higher for women under 55. Incidence for CVT, HUS and CVT with ITP or HIT was higher for women in all age groups. Incidence of PE and CVT increased significantly over the 5-year period, while DVT rates decreased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results are the first US estimates for the incidence of thrombotic and rare events of interest in a large, commercially insured US population. Findings provide a critically important reference for determining excess morbidity associated with COVID-19 and more generally for vaccine pharmacovigilance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-054669","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:38:23Z","timestamp":1644406703000},"page":"e054669","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-736X","authenticated-orcid":false,"given":"Susan C","family":"Weller","sequence":"first","affiliation":[{"name":"Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"},{"name":"Family Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"},{"name":"Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-144X","authenticated-orcid":false,"given":"Laura","family":"Porterfield","sequence":"additional","affiliation":[{"name":"Family Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"},{"name":"Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-0323","authenticated-orcid":false,"given":"John","family":"Davis","sequence":"additional","affiliation":[{"name":"4. Population Health Sciences MD\/PhD Program, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-3902","authenticated-orcid":false,"given":"Gregg S","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6867-2618","authenticated-orcid":false,"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"5. Epidemiology and Biostatistics Consulting Unit, Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-653X","authenticated-orcid":false,"given":"Jacques","family":"Baillargeon","sequence":"additional","affiliation":[{"name":"Preventive Medicine and Population Health, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"2025120600430376000_12.2.e054669.1","unstructured":"EMA Press Office . AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets, 2021. Eur. Med. Agency. Available: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood [Accessed 12 Apr 2021]."},{"key":"2025120600430376000_12.2.e054669.2","unstructured":"Steenhuysen J, Pushkala A . J&J COVID-19 vaccine under EU review over blood clots., 2021. Reuters. Available: https:\/\/www.reuters.com\/article\/us-health-coronavirus-europe-vaccines-idUSKBN2BW2FI [Accessed 12 Apr 2021]."},{"key":"2025120600430376000_12.2.e054669.3","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"2025120600430376000_12.2.e054669.4","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-03-0205"},{"key":"2025120600430376000_12.2.e054669.5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(21)00762-5","article-title":"Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?","volume":"397","author":"\u00d8stergaard","year":"2021","journal-title":"Lancet"},{"key":"2025120600430376000_12.2.e054669.6","unstructured":"Williame C , Dodd C , Gini R , et al . Background rates of adverse events of special interest for monitoring COVID-19 vaccines., 2021. Available: http:\/\/www.encepp.eu\/documents\/ACCESS_Report_BGR_20210430_v.1.2.pdf [Accessed 06 May 2021]."},{"key":"2025120600430376000_12.2.e054669.7","unstructured":"Optum De-Identified market clarity data (2007-2020), 2021. Available: https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/5302_Data_Assets_Chart_Sheet_ISPOR.pdf"},{"key":"2025120600430376000_12.2.e054669.8","unstructured":"Rothman KJ , Lash TL , Greenland S . Third, Mid-cycle revision edition. Philadelphia Baltimore New York: LWW, 2012."},{"key":"2025120600430376000_12.2.e054669.9","unstructured":"SAS Institute inc . Base SAS\u00ae 9.3 Procedures Guide: Statistical Procedures. Version 9.4. NC: Cary, 2016."},{"key":"2025120600430376000_12.2.e054669.10","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2020.1769988"},{"key":"2025120600430376000_12.2.e054669.11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jamainternmed.2021.0488","article-title":"Incidence of 30-day venous thromboembolism in adults tested for SARS-CoV-2 infection in an integrated health care system in northern California","volume":"181","author":"Roubinian","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025120600430376000_12.2.e054669.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.6.585"},{"key":"2025120600430376000_12.2.e054669.13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","article-title":"Incidence of venous thromboembolism: a community-based study in Western France","volume":"83","author":"Oger","year":"2000","journal-title":"Thromb Haemost"},{"key":"2025120600430376000_12.2.e054669.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.01.018"},{"key":"2025120600430376000_12.2.e054669.15","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-08-0506"},{"key":"2025120600430376000_12.2.e054669.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02450.x"},{"key":"2025120600430376000_12.2.e054669.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.03.041"},{"key":"2025120600430376000_12.2.e054669.18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2020.10.030","article-title":"Current estimates of the incidence of acute venous thromboembolic disease in Canada: a meta-analysis","volume":"197","author":"Payne","year":"2021","journal-title":"Thromb Res"},{"key":"2025120600430376000_12.2.e054669.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010598"},{"key":"2025120600430376000_12.2.e054669.20","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.671453"},{"key":"2025120600430376000_12.2.e054669.21","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.013617"},{"key":"2025120600430376000_12.2.e054669.22","doi-asserted-by":"publisher","DOI":"10.1177\/1941874416648198"},{"key":"2025120600430376000_12.2.e054669.23","first-page":"58","article-title":"Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported","volume":"49","author":"Handley","year":"2020","journal-title":"Health Inf Manag"},{"key":"2025120600430376000_12.2.e054669.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01415.x"},{"key":"2025120600430376000_12.2.e054669.25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2015.09.087","article-title":"Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females","volume":"34","author":"Yih","year":"2016","journal-title":"Vaccine"},{"key":"2025120600430376000_12.2.e054669.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1114"},{"key":"2025120600430376000_12.2.e054669.27","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-054669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:43:14Z","timestamp":1765010594000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-054669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/bmjopen-2021-054669"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-054669","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.13.21258854","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}